SCYNEXIS, Inc. (SCYX)Healthcare | Drug Manufacturers - Specialty & Generic | Jersey City, United States | NasdaqCM
3.96 USD
-0.03
(-0.752%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:55 a.m. EDT
The investment case here is broken. The company is hemorrhaging cash with negative free cash flow and operating margins of -33%, while revenue has collapsed by 83% year-over-year. The balance sheet is fragile, and the stock has suffered a catastrophic 98% decline over the last nine years, with every single year being negative. This is not a value trap; it is a failing business where the market has correctly priced out the risk of insolvency or total obsolescence. The recent reverse stock split and lack of dividends confirm the company is in distress mode. While analysts project a massive recovery to the $30s, the fundamental reality of shrinking revenues and burning cash makes such targets delusional without a proven, successful product launch that isn't currently materializing. The options market agrees, with traders aggressively buying protection at lower strikes. There is no margin of safety here, only a deep value trap. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.244746 |
| AutoETS | 0.261778 |
| AutoARIMA | 0.261783 |
| AutoTheta | 0.342114 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 0.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 0.86 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.906 |
| Revenue per Share | 2.496 |
| Market Cap | 39,400,452 |
| Forward P/E | -1.71 |
| Beta | 1.06 |
| Profit Margins | -53.26% |
| Website | https://www.scynexis.com |
As of Oct. 10, 2026, 10:55 a.m. EDT: Speculators are positioning for a sharp downside move, evidenced by heavy new volume in October puts at the $2.50 strike compared to minimal call activity. While there is some open interest in out-of-the-money calls ($7.50), the immediate flow is overwhelmingly bearish, suggesting a bet on further price compression rather than a rebound.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.37656248 |
| Address1 | 1 Evertrust Plaza |
| Address2 | 13th Floor |
| All Time High | 1,200.0 |
| All Time Low | 3.53 |
| Ask | 6.23 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 224,040 |
| Average Daily Volume3 Month | 283,023 |
| Average Volume | 283,023 |
| Average Volume10Days | 224,040 |
| Beta | 1.06 |
| Bid | 3.93 |
| Bid Size | 2 |
| Book Value | 6.727 |
| City | Jersey City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.96 |
| Current Ratio | 9.654 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.08 |
| Day Low | 3.9 |
| Debt To Equity | 2.906 |
| Display Name | SCYNEXIS |
| Dividend Date | 1,594,944,000 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | -0.663 |
| Enterprise Value | -12,737,548 |
| Eps Current Year | -2.91 |
| Eps Forward | -2.315 |
| Eps Trailing Twelve Months | -0.89 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.9024 |
| Fifty Day Average Change | -0.9424 |
| Fifty Day Average Change Percent | -0.19223237 |
| Fifty Two Week Change Percent | -37.656246 |
| Fifty Two Week High | 9.12 |
| Fifty Two Week High Change | -5.16 |
| Fifty Two Week High Change Percent | -0.56578946 |
| Fifty Two Week Low | 3.53 |
| Fifty Two Week Low Change | 0.43000007 |
| Fifty Two Week Low Change Percent | 0.12181305 |
| Fifty Two Week Range | 3.53 - 9.12 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,399,037,400,000 |
| Float Shares | 7,350,871 |
| Forward Eps | -2.315 |
| Forward P E | -1.7105831 |
| Free Cashflow | -7,323,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 18 |
| Fullday Change | -0.029999971 |
| Fullday Change Percent | -0.751879 |
| Fullday Price | 3.96 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 19,216,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02053 |
| Held Percent Institutions | 0.62105 |
| Implied Shares Outstanding | 9,949,609 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,780,272,000 |
| Last Split Factor | 1:8 |
| Long Business Summary | SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. |
| Long Name | SCYNEXIS, Inc. |
| Market | us_market |
| Market Cap | 39,400,452 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_798887 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -10,235,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 45,419,965 |
| Number Of Analyst Opinions | 3 |
| Open | 4.0 |
| Operating Cashflow | -13,309,000 |
| Operating Margins | -33.08511 |
| Payout Ratio | 0.0 |
| Phone | 201 884 5485 |
| Previous Close | 3.99 |
| Price Eps Current Year | -1.3608247 |
| Price Hint | 4 |
| Price To Book | 0.5886725 |
| Price To Sales Trailing12 Months | 2.050398 |
| Profit Margins | -0.53263 |
| Quick Ratio | 9.285 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -0.751879 |
| Regular Market Day High | 4.08 |
| Regular Market Day Low | 3.9 |
| Regular Market Day Range | 3.9 - 4.08 |
| Regular Market Open | 4.0 |
| Regular Market Previous Close | 3.99 |
| Regular Market Price | 3.96 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 44,559 |
| Return On Assets | -0.20823 |
| Return On Equity | -0.18375999 |
| Revenue Growth | -0.828 |
| Revenue Per Share | 2.496 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 9,949,609 |
| Shares Percent Shares Out | 0.059699997 |
| Shares Short | 594,318 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 454,005 |
| Short Name | SCYNEXIS, Inc. |
| Short Percent Of Float | 0.060900003 |
| Short Ratio | 1.34 |
| Source Interval | 15 |
| State | NJ |
| Symbol | SCYX |
| Target High Price | 44.0 |
| Target Low Price | 32.0 |
| Target Mean Price | 36.33333 |
| Target Median Price | 33.0 |
| Total Cash | 54,083,000 |
| Total Cash Per Share | 5.436 |
| Total Debt | 1,945,000 |
| Total Revenue | 19,216,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.89 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.62766 |
| Two Hundred Day Average Change | -1.6676598 |
| Two Hundred Day Average Change Percent | -0.29633272 |
| Type Disp | Equity |
| Volume | 44,559 |
| Website | https://www.scynexis.com |
| Zip | 07,302-6548 |